Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From August 8th, 2007 to Jannuary 14th, 2008
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
- Report date:
- 2008
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- July 27, 1995
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Directive 96 / 54 / EC, B. 7. "Repeated dose (28 days) toxicity (oral)
- Version / remarks:
- September 30, 1996
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2,2`-[6-(phenylamino)-1,3,5-triazine-2,4-diyl]diphenol
- Cas Number:
- 1248-66-4
- Molecular formula:
- C21H16N4O2
- IUPAC Name:
- 2,2`-[6-(phenylamino)-1,3,5-triazine-2,4-diyl]diphenol
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: RCC Ltd
- Age at delivery: 6 weeks
- Weight at study initiation: Body weight range (at acclimatization): Males: 137.7 to 160.4 g (Mean: 149.0 ± 6.9 g). Females: 111.3 g to 130.6 g (Mean: 118.7 ± 5.2 g).
- Housing: in groups of five in Makrolon type-4 cages with wire mesh tops.
- Diet: pelleted standard Kliba Nafag 3433 rat mainenance diet ad libitum.
- Water: community tap water from Itingen ad libitum.
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 30 - 70%
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12 hours fluorescent light/ 12 hour dark
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Details on oral exposure:
- The dose formulations were prepared weekly. The test item was weighed into a glass beaker on a tared Mettler balance and the vehicle (PEG 300) added (weight:volume). The mixtures were stirred using a magnetic stirrer and stored at room temperature (15 - 25 °C). Homogeneity of the test item in the vehicle was maintained during the daily administration period using a magnetic stirrer.
The following doses were administered:
Group 1: 0 mg/kg/day
Group 2: 50 mg/kg/day
Group 3: 200 mg/kg/day
Group 4: 1000 mg/kg/day
The dose levels were selected based on a previous dose range finding toxicity study in Wistar rats, using dose levels of 200, 600, and1000 mg/kg/day.
The dose volume was 5 ml/kg body weight. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- HPLC
On the first treatment day and once during week 3 a sample of the control group as well as three samples (top, middle and bottom) of about 2 g of each concentration were taken prior to dosing for analysis of homogeneity and concentration. An additional sample of the control group as well as three samples (top, middle and bottom) of about 2 g of each concentration were taken after the end of in life phase. A sample of about 2 g of each concentration was taken five hours and 7 days after commencement of dosing (first treatment day) and on an additional time point after end of in life phase to confirm stability. Additional dose formulation preparation and analysis were performed after end of in life because samples prepared on day 1 needed to be reanalyzed due to technical problems but were inadvertently discarded. The aliquots for analysis of dose formulations were frozen (-20 ± 5 °C) and delivered to RCC Ltd, Itingen /Switzerland and stored there at -20 ± 5 °C until analysis. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily; 7 days/week for 4 weeks;
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
50 mg/kg body weight/day
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
200 mg/kg body weight/day
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
1000 mg/kg body weight/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Doses are based on dose-range-finding
Examinations
- Observations and examinations performed and frequency:
- Viability/Mortality, General Cageside Observations/ Detailed Clinical Observations (weekly), Grip strenght, Locomotor activity, food consumption, body weight, hematology, clinical biochemistry, urinalysis, organ weight, macroscopic findings, microscopic findings.
- Sacrifice and pathology:
- HISTOPATHOLOGY: Yes
Gross Pathology: yes - Statistics:
- Dunnett-test
Steel-test
Fisher`s exact-test
Armitage/Cochran Trend Test
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- One animal (male, 50 mg/kg(day) died spontaneously on treatment day 5. This spontaneously death was not considered to be test-related.
No test item-related clinical signs were observed.
Inreased locomotor activity in both sexes at 1000 mg/kg/day.
Absolute and relative food consumption and body weight was not influenced by the treatment during the treatment and recovery period.
No test item-related alterations in the mean fore- and handlimb grip strenght were recorded in rats at any dose levels.
No test item-related findings in hematology were recorded.
No test item-related changes in clinical biochemistry and urinalysis.
Increased mean thymus/body weight ratio and mean thymus/brain weight ratio was recorded in males at 1000 mg/kg/day at the end of the recovery period. As there were no histopathological correlates this finding was considered to be incidental. No further findings were recorded.
No test item-related macroscopic lesions were observed.
Minimal hypertrophy of the zona fasciculata was recorded in male animals and slight hypertrophy of the zona fasciculata in one female. Minimal hypertrophy of the zona glomerulosa in one male animal.
Minimal increased erythropoiesis was recorded in female animals; after a 14-day-treatment-free recovery period none of these changes were present
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- > 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Increased locomotor activity in both sexes at 1000 mg/kg/day
- Dose descriptor:
- LOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: Increased locomotor activity in both sexes at 1000 mg/kg/day
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- not subject of classification and labeling
- Executive summary:
Oral administration of test item to Wistar rats of both sexes at doses of 50, 200 and 1000 mg/kg/day, for 28 days resulted in a statistically significant increase in total locomotor activity was observed in males and females at 1000 mg/kg/day. A minimal increased erythropoiesis in the bone marrow was recorded in female animals of group 4. Histopthological findings were reported in the adrenals (minimal hypertrophy of the zona fasciculata in male animals of groups 2, 3 and 4, and slight hypertrophy of the zona fasciculata in one female animal of group 4, minimal hypertrophy of the zona glomerulosa in one male animal of group 2) and an increase in mean adrenal weight, mean adrenal to terminal body weight ratio, and mean adrenal to brain weight ratio in males at 50, 200 and 1000 mg/kg/day. These findings in adrenals were considered to be stress-related and not to be test item-related. After a 14 day treatment-free recovery period none of these histopathological changes were present.
A no-observed-effect-level (NOEL) could not be established within this study.
Due to the increased locomotor activity in both sexes at 1000 mg/kg/day the no-adverse-effect-level (NOAEL) of test item was established at 200 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.